Retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors under investigation for obesity, metabolic syndrome, energy expenditure, and cardiovascular risk factor research.
| Molecular Weight | 4723.45 g/mol |
| Purity | >98% |
| Form | Lyophilized powder |
| Storage | -20°C |
Science-backed research overview for this compound
Retatrutide is a "triple agonist" peptide that targets three different metabolic receptors: GLP-1 (Glucagon-like Peptide-1), GIP (Glucose-dependent Insulinotropic Polypeptide), and Glucagon. It represents the next frontier in metabolic and obesity research.
By activating GLP-1 and GIP receptors, Retatrutide stimulates insulin secretion and suppresses appetite. The addition of the Glucagon receptor agonist is the key differentiator; it increases energy expenditure (fat burning) by signaling the liver to mobilize stored energy, leading to potentially superior weight loss results in research models.
Retatrutide is currently being studied for its ability to produce significant weight loss (up to 24% in clinical trials) and its impact on non-alcoholic fatty liver disease (NAFLD). It is considered one of the most powerful tools ever discovered for the study of metabolic health and chronic weight management.